About 30% of human breast cancers are human epidermal growth factor receptor 2(HER2)+. This particular biological portrait is characterized by the overexpression of HER2 receptor with the subsequent deregulation of do...About 30% of human breast cancers are human epidermal growth factor receptor 2(HER2)+. This particular biological portrait is characterized by the overexpression of HER2 receptor with the subsequent deregulation of downstream pathways, which control cellular survival and proliferation. The most effective treatment for HER2+cancer is represented by therapy with HER2-targeted agents. Anti-HER2 therapy dramatically improves clinical outcomes, although it shows some limitations in achieving a proper treatment. These drawbacks of HER2-targeted therapy may be overcome with the development of HER2-targeted drug delivery nanodevices. These nanoparticles possess an internal three-dimensional compartimentalization, which allows to combine the specific target recognition with their capability to act as a drug reservoir for the selective delivery of chemotherapics to tumor sites. Moreover, nanoparticles useful in photothermal ablation or in photodynamic therapy have been functionalized in order to match specificity in tumor cell recognition and suitable chemical properties. Here, we summarize the state of the art concerning the HER2+breast cancer and anti-HER2 therapy, in particular deepening the contribution of the nanomedicine. Description of preclinical studies performed with HER2-targeted na-noparticles for HER2+ breast cancer therapy will be preceded by an overview on HER2-targeting molecules and nano-conjugation strategies. Further investigation will be necessary to introduce these nano-drugs in clinical practice; however promising results encourage an upcoming translation of this research for the next future.展开更多
Dear Editor,Microcalcifications(MCs)are common findings in mammography and can be indicative of different degrees of malignancy,thus requiring multiple stereotaxis vacuumassisted biopsies under mammography to identify...Dear Editor,Microcalcifications(MCs)are common findings in mammography and can be indicative of different degrees of malignancy,thus requiring multiple stereotaxis vacuumassisted biopsies under mammography to identify and characterize breast cancer[1,2].In many cases,however,the presence of MCs is not associated with the presence of a tumor.Therefore,a better understanding of the physical-chemical properties of MCs is needed to assess the relationship between their presence and breast cancer.展开更多
文摘About 30% of human breast cancers are human epidermal growth factor receptor 2(HER2)+. This particular biological portrait is characterized by the overexpression of HER2 receptor with the subsequent deregulation of downstream pathways, which control cellular survival and proliferation. The most effective treatment for HER2+cancer is represented by therapy with HER2-targeted agents. Anti-HER2 therapy dramatically improves clinical outcomes, although it shows some limitations in achieving a proper treatment. These drawbacks of HER2-targeted therapy may be overcome with the development of HER2-targeted drug delivery nanodevices. These nanoparticles possess an internal three-dimensional compartimentalization, which allows to combine the specific target recognition with their capability to act as a drug reservoir for the selective delivery of chemotherapics to tumor sites. Moreover, nanoparticles useful in photothermal ablation or in photodynamic therapy have been functionalized in order to match specificity in tumor cell recognition and suitable chemical properties. Here, we summarize the state of the art concerning the HER2+breast cancer and anti-HER2 therapy, in particular deepening the contribution of the nanomedicine. Description of preclinical studies performed with HER2-targeted na-noparticles for HER2+ breast cancer therapy will be preceded by an overview on HER2-targeting molecules and nano-conjugation strategies. Further investigation will be necessary to introduce these nano-drugs in clinical practice; however promising results encourage an upcoming translation of this research for the next future.
基金European Union’s Horizon(731019)and Ministero della Salute(Ricerca Corrente).
文摘Dear Editor,Microcalcifications(MCs)are common findings in mammography and can be indicative of different degrees of malignancy,thus requiring multiple stereotaxis vacuumassisted biopsies under mammography to identify and characterize breast cancer[1,2].In many cases,however,the presence of MCs is not associated with the presence of a tumor.Therefore,a better understanding of the physical-chemical properties of MCs is needed to assess the relationship between their presence and breast cancer.
